XBiotech Announces Research Collaboration with Renowned Gastroenterologist
November 17 2016 - 8:00AM
XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic
antibodies, announced today commencement of a collaboration with a
research team at Case Western Reserve University (CWRU) School of
Medicine headed by leading gastroenterologist, Fabio Cominelli,
M.D., Ph.D. Dr. Cominelli and his research team will conduct
pre-clinical studies to help develop new treatments for
Inflammatory Bowel Disease (IBD) using the company’s pioneering
approach to using natural human antibody therapy to neutralize
harmful inflammation. Dr. Cominelli is a world-leading expert in
inflammatory bowel disease. His group was the first to report that
specific blockade of interleukin-1 (IL-1) was effective in reducing
disease severity in colitis and that deregulated inflammation is a
cause of auto-inflammatory diseases, including IBD.
Dr. Cominelli is Chief of the Division of
Gastroenterology and Liver Disease and Director of the Digestive
Health Institute at CWRU School of Medicine in Cleveland and Chief
Scientific Officer of the Digestive Health Institute at University
Hospitals Cleveland Medical Center. Dr. Cominelli is also the
Hermann Menges Jr. Chair in Internal Medicine and Professor at CWRU
School of Medicine. Dr. Cominelli has a professional interest in
Crohn's disease, gastrointestinal (GI) cancer, IBD and ulcerative
colitis. He is a member of the American Society for Clinical
Investigation and Association of American Physicians. He has
previously earned a NIH Merit Award. His work has been published in
a number of peer-reviewed journals, such as Inflammatory Bowel
Diseases and The Journal of Immunology. Dr. Cominelli earned his
medical degree at Universita’ Degli Studi di Firenze in Florence,
Italy, where he also completed his internal medicine residency. He
completed his gastroenterology fellowship at Harbor-UCLA Medical
Center in Torrance, California.
Dr. Cominelli stated, “I have researched IL-1’s
role in disease severity in colitis for many years, and am excited
about the opportunity to be able to selectively inhibit IL-1 alpha
to better define its role in IBD. These results will help shape the
design of future clinical trials as we look for new and better
treatments for this wide-spread condition.”
John Simard, the Company’s President and Chief
Executive Officer, commented, “Dr. Cominelli’s past research has
formed the foundation for clinical trials with important
implications for new treatments for patients suffering from
inflammatory diseases of the bowl. We are hopeful that this
collaboration will provide for further advances in treatment.”
About Inflammatory Bowel DiseaseInflammatory
bowel disease (IBD) is a common condition involving chronic
inflammation of the digestive tract. IBD primarily includes
ulcerative colitis and Crohn's disease, both of which are typically
associated with severe diarrhea, pain, fatigue and weight loss. IBD
can have a devastating impact on quality of life and in some cases
lead to life-threatening complications. There are approximately 1.6
million Americans and 5 million people worldwide suffering from IBD
with as many as 70,000 new cases diagnosed yearly in the U.S1.
About True Human™ Therapeutic AntibodiesUnlike
previous generations of antibody therapies, XBiotech’s True Human™
antibodies are derived without modification from individuals who
possess natural immunity to certain diseases. With discovery and
clinical programs across multiple disease areas, XBiotech’s True
Human antibodies have the potential to harness the body’s natural
immunity to fight disease with increased safety, efficacy and
tolerability.
About XBiotech XBiotech is
a fully integrated global biosciences company dedicated to
pioneering the discovery, development and commercialization of
therapeutic antibodies based on its True Human™ proprietary
technology. XBiotech currently is advancing a robust pipeline of
antibody therapies to redefine the standards of care in oncology,
inflammatory conditions and infectious diseases. Headquartered in
Austin, Texas, XBiotech also is leading the development of
innovative biotech manufacturing technologies designed to more
rapidly, cost-effectively and flexibly produce new therapies
urgently needed by patients worldwide. For more information, visit
www.xbiotech.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements, including declarations regarding management's beliefs
and expectations that involve substantial risks and uncertainties.
In some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "would," "could,"
"expects," "plans," "contemplate," "anticipates," "believes,"
"estimates," "predicts," "projects," "intend" or "continue" or the
negative of such terms or other comparable terminology, although
not all forward-looking statements contain these identifying words.
Forward-looking statements are subject to inherent risks and
uncertainties in predicting future results and conditions that
could cause the actual results to differ materially from those
projected in these forward-looking statements. These risks and
uncertainties are subject to the disclosures set forth in the "Risk
Factors" section of certain of our SEC filings. Forward-looking
statements are not guarantees of future performance, and our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements that we make in this
press release speak only as of the date of this press release. We
assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
1 The Facts About Inflammatory Bowel Disease. Crohn’s &
Colitis Foundation of America. November 2014.
Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Mar 2024 to Apr 2024
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Apr 2023 to Apr 2024